{"url_path":"/sec/aqst/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1398733/0001398733-26-000030-index.html","accession_number":"0001398733-26-000030","cik":"0001398733","ticker":"AQST","issuer_name":"Aquestive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1398733/0001398733-26-000030-index.html","primary_entity_key":"0001398733","primary_entity_name":"Aquestive Therapeutics, Inc."},"word_count":445,"has_tables":true,"body_markdown":"aqst-20260331\n0001398733December 312026Q1Falsehttp://fasb.org/us-gaap/2025#ManufacturedProductOtherMemberhttp://fasb.org/us-gaap/2025#ManufacturedProductOtherMemberxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureaqst:segmentaqst:leaseaqst:paymentaqst:instrumentaqst:pricing_periodaqst:pending_caseaqst:renewal_option00013987332026-01-012026-03-3100013987332026-05-1100013987332026-03-3100013987332025-12-3100013987332025-01-012025-03-310001398733us-gaap:CommonStockMember2025-12-310001398733us-gaap:AdditionalPaidInCapitalMember2025-12-310001398733us-gaap:RetainedEarningsMember2025-12-310001398733aqst:AtTheMarketOfferingMemberus-gaap:CommonStockMember2026-01-012026-03-310001398733aqst:AtTheMarketOfferingMemberus-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001398733aqst:AtTheMarketOfferingMember2026-01-012026-03-310001398733us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001398733us-gaap:CommonStockMember2026-01-012026-03-310001398733us-gaap:RetainedEarningsMember2026-01-012026-03-310001398733us-gaap:CommonStockMember2026-03-310001398733us-gaap:AdditionalPaidInCapitalMember2026-03-310001398733us-gaap:RetainedEarningsMember2026-03-310001398733us-gaap:CommonStockMember2024-12-310001398733us-gaap:AdditionalPaidInCapitalMember2024-12-310001398733us-gaap:RetainedEarningsMember2024-12-3100013987332024-12-310001398733aqst:AtTheMarketOfferingMemberus-gaap:CommonStockMember2025-01-012025-03-310001398733aqst:AtTheMarketOfferingMemberus-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001398733aqst:AtTheMarketOfferingMember2025-01-012025-03-310001398733us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001398733us-gaap:CommonStockMember2025-01-012025-03-310001398733us-gaap:RetainedEarningsMember2025-01-012025-03-310001398733us-gaap:CommonStockMember2025-03-310001398733us-gaap:AdditionalPaidInCapitalMember2025-03-310001398733us-gaap:RetainedEarningsMember2025-03-3100013987332025-03-310001398733aqst:EquityDistributionAgreementMember2019-09-012026-03-310001398733aqst:AmendedEquityDistributionAgreementMember2024-04-032024-04-030001398733srt:MaximumMemberaqst:EquityDistributionAgreementMember2024-04-232024-04-230001398733aqst:AmendedEquityDistributionAgreementMember2026-01-012026-03-310001398733aqst:AmendedEquityDistributionAgreementMember2025-01-012025-03-310001398733aqst:AmendedEquityDistributionAgreementMember2026-03-310001398733aqst:UnderwrittenPublicOfferingMember2025-08-142025-08-140001398733aqst:UnderwrittenPublicOfferingMember2025-08-140001398733aqst:SeniorSecuredNotes13.5DueNovember12028Memberus-gaap:SeniorNotesMember2026-03-310001398733aqst:ReportableSegmentMember2026-01-012026-03-310001398733aqst:ReportableSegmentMember2025-01-012025-03-310001398733aqst:AnaphylmMemberaqst:ReportableSegmentMember2026-01-012026-03-310001398733aqst:AnaphylmMemberaqst:ReportableSegmentMember2025-01-012025-03-310001398733aqst:AQST108Memberaqst:ReportableSegmentMember2026-01-012026-03-310001398733aqst:AQST108Memberaqst:ReportableSegmentMember2025-01-012025-03-310001398733aqst:PersonnelCostsMemberaqst:ReportableSegmentMember2026-01-012026-03-310001398733aqst:PersonnelCostsMemberaqst:ReportableSegmentMember2025-01-012025-03-310001398733aqst:OtherMemberaqst:ReportableSegmentMember2026-01-012026-03-310001398733aqst:OtherMemberaqst:ReportableSegmentMember2025-01-012025-03-310001398733srt:MaximumMember2026-01-012026-03-310001398733aqst:ManufactureAndSupplyRevenueMember2026-01-012026-03-310001398733aqst:ManufactureAndSupplyRevenueMember2025-01-012025-03-310001398733aqst:LicenseAndRoyaltyRevenueMember2026-01-012026-03-310001398733aqst:LicenseAndRoyaltyRevenueMember2025-01-012025-03-310001398733aqst:CoDevelopmentAndResearchFeesMember2026-01-012026-03-310001398733aqst:CoDevelopmentAndResearchFeesMember2025-01-012025-03-310001398733aqst:ProprietaryProductRevenueMember2026-01-012026-03-310001398733aqst:ProprietaryProductRevenueMember2025-01-012025-03-310001398733aqst:LicenseAndRoyaltyRevenueMemberaqst:ZevraAndCommaveTherapeuticsAgreementMember2026-01-012026-03-310001398733country:US2026-01-012026-03-310001398733country:US2025-01-012025-03-310001398733us-gaap:NonUsMember2026-01-012026-03-310001398733us-gaap:NonUsMember2025-01-012025-03-310001398733aqst:TradeAccountsReceivableDoubtfulAccountsMember2025-12-310001398733aqst:TradeAccountsReceivableDoubtfulAccountsMember2026-03-310001398733aqst:TradeAccountsReceivableSalesRelatedMember2025-12-310001398733aqst:TradeAccountsReceivableSalesRelatedMember2024-12-310001398733aqst:TradeAccountsReceivableSalesRelatedMember2026-01-012026-03-310001398733aqst:TradeAccountsReceivableSalesRelatedMember2025-01-012025-12-310001398733aqst:TradeAccountsReceivableSalesRelatedMember2026-03-310001398733us-gaap:TradeAccountsReceivableMember2026-03-310001398733aqst:OtherReceivablesAndAccruedExpensesMember2026-03-310001398733us-gaap:TradeAccountsReceivableMember2025-12-310001398733aqst:OtherReceivablesAndAccruedExpensesMember2025-12-310001398733aqst:IndiviorMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2026-01-012026-03-310001398733aqst:ZevraMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2026-01-012026-03-310001398733aqst:IndiviorMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2026-01-012026-03-310001398733aqst:AssertioHoldingsIncMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2026-01-012026-03-310001398733aqst:IndiviorMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2025-01-012025-03-310001398733aqst:HyperaMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2025-01-012025-03-310001398733aqst:IndiviorMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001398733aqst:HyperaMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001398733aqst:PurchaseAndSaleAgreementMemberaqst:RTWInvestmentsLPMember2025-08-132025-08-130001398733aqst:PurchaseAndSaleAgreementMemberaqst:RTWInvestmentsLPMemberus-gaap:SeniorNotesMember2025-08-130001398733aqst:PurchaseAndSaleAgreementMemberaqst:RTWInvestmentsLPMembersrt:MinimumMember2025-08-132025-08-130001398733aqst:PurchaseAndSaleAgreementMemberaqst:RTWInvestmentsLPMembersrt:MaximumMember2025-08-132025-08-130001398733aqst:PurchaseAndSaleAgreementMemberaqst:RTWInvestmentsLPMember2025-08-130001398733aqst:PurchaseAndSaleAgreementMemberaqst:RTWInvestmentsLPMember2026-03-310001398733aqst:PurchaseAndSaleAgreementMemberaqst:RTWInvestmentsLPMember2025-12-3100013987332026-03-030001398733srt:MinimumMember2026-03-0300013987332026-03-032026-03-030001398733aqst:CommercialExploitationAgreementWithIndiviorMember2026-01-012026-03-310001398733aqst:CommercialExploitationAgreementWithIndiviorMember2023-03-022023-03-020001398733aqst:LicenseAndRoyaltyRevenueMemberaqst:LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember2020-05-212020-05-210001398733aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember2020-10-232020-10-230001398733aqst:LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember2020-10-232020-10-230001398733aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember2020-10-232020-10-230001398733aqst:MonetizationAgreementMemberaqst:MarathonPangolinRoyaltyLLCMember2020-11-032020-11-030001398733aqst:MonetizationAgreementMemberaqst:MarathonPangolinRoyaltyLLCMember2020-11-032026-03-310001398733srt:MaximumMemberaqst:MarathonPangolinRoyaltyLLCMember2020-11-032020-11-030001398733aqst:LicenseAndRoyaltyRevenueMemberaqst:ZevraAndCommaveTherapeuticsAgreementMemberus-gaap:SubsequentEventMember2026-04-302026-04-300001398733aqst:LicenseSupplyAgreementMemberaqst:AtnahsPharmaUKLimitedMember2022-09-262022-09-260001398733aqst:LicenseSupplyAgreementMemberaqst:AtnahsPharmaUKLimitedAmendedAgreementMember2023-03-272023-03-270001398733aqst:AssertioHoldingsIncMember2022-10-262022-10-260001398733aqst:SecuritiesPurchaseAgreementMember2022-06-012022-06-300001398733aqst:ExistingWarrantsMember2023-08-010001398733aqst:NewWarrantsMember2023-08-010001398733aqst:SeniorSecuredNotes13.5DueNovember12028Memberus-gaap:SeniorNotesMember2023-11-010001398733srt:MinimumMember2023-11-012023-11-010001398733srt:MaximumMember2023-11-012023-11-0100013987332023-11-010001398733aqst:CommonStockWarrantsMember2026-03-030001398733aqst:CommonStockWarrantsMembersrt:MinimumMember2026-03-030001398733srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2026-03-310001398733srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2026-03-310001398733us-gaap:MachineryAndEquipmentMember2026-03-310001398733us-gaap:MachineryAndEquipmentMember2025-12-310001398733srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2026-03-310001398733srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2026-03-310001398733us-gaap:FurnitureAndFixturesMember2026-03-310001398733us-gaap:FurnitureAndFixturesMember2025-12-310001398733us-gaap:LeaseholdImprovementsMember2026-03-310001398733us-gaap:LeaseholdImprovementsMember2025-12-310001398733srt:MinimumMemberaqst:ComputerNetworkEquipmentAndSoftwareMember2026-03-310001398733srt:MaximumMemberaqst:ComputerNetworkEquipmentAndSoftwareMember2026-03-310001398733aqst:ComputerNetworkEquipmentAndSoftwareMember2026-03-310001398733aqst:ComputerNetworkEquipmentAndSoftwareMember2025-12-310001398733us-gaap:ConstructionInProgressMember2026-03-310001398733us-gaap:ConstructionInProgressMember2025-12-310001398733srt:MinimumMember2026-03-310001398733srt:MaximumMember2026-03-310001398733us-gaap:RoyaltyMemberaqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember2020-04-012020-06-300001398733aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember2026-03-310001398733aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember2025-12-310001398733aqst:SeniorSecuredNotes13.5DueNovember12028Memberus-gaap:SeniorNotesMember2023-11-012023-11-010001398733aqst:TwelvePointFiveSeniorSecuredNotesDueJune302025Memberus-gaap:SeniorNotesMember2026-03-310001398733aqst:RoyaltyObligationsMemberus-gaap:SeniorNotesMember2023-11-012023-11-010001398733aqst:RedemptionScenario1Memberaqst:SeniorSecuredNotes13.5DueNovember12028Memberus-gaap:SeniorNotesMember2023-11-012023-11-010001398733aqst:RedemptionScenario1Memberus-gaap:SeniorNotesMember2023-11-012023-11-010001398733aqst:RedemptionScenario2Memberaqst:SeniorSecuredNotes13.5DueNovember12028Memberus-gaap:SeniorNotesMember2023-11-012023-11-010001398733aqst:ABLFacilityMember2023-11-012023-11-010001398733aqst:ABLFacilityMember2023-11-010001398733aqst:TermLoanFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2026-05-122026-05-120001398733aqst:TermLoanFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2026-05-120001398733aqst:SeniorSecuredNotes13.5DueNovember12028Memberus-gaap:SeniorNotesMemberus-gaap:SubsequentEventMember2026-05-120001398733aqst:SeniorSecuredNotes13.5DueNovember12028Memberus-gaap:SeniorNotesMemberus-gaap:SubsequentEventMember2026-05-122026-05-120001398733us-gaap:MeasurementInputDiscountRateMember2026-03-310001398733aqst:MeasurementInputProbabilityOfSuccessMember2026-03-310001398733aqst:RoyaltyObligationsMemberus-gaap:UnsecuredDebtMember2025-12-310001398733aqst:SeniorSecuredNotes13.5DueNovember12028Memberus-gaap:SeniorNotesMember2025-12-310001398733aqst:SeniorSecuredNotes13.5DueNovember12028Memberus-gaap:SeniorNotesMember2026-01-012026-03-310001398733aqst:RoyaltyObligationsMemberus-gaap:SeniorNotesMember2026-03-310001398733aqst:RoyaltyObligationsMemberus-gaap:SeniorNotesMember2023-11-010001398733aqst:SeniorSecuredNotes13.5DueNovember12028Member2026-01-012026-03-310001398733aqst:RoyaltyRightAgreementsMember2026-01-012026-03-310001398733aqst:SeniorSecuredNotes13.5DueNovember12028Memberus-gaap:SeniorNotesMember2025-03-310001398733aqst:SeniorSecuredNotes13.5DueNovember12028Member2025-01-012025-03-310001398733aqst:RoyaltyRightAgreementsMember2025-01-012025-03-310001398733aqst:RoyaltyObligationsMemberus-gaap:UnsecuredDebtMember2026-03-310001398733aqst:TwelvePointFiveSeniorSecuredNotesDueJune302025Member2019-07-150001398733aqst:FirstAdditionalWarrantOfferingMembersrt:MaximumMember2019-07-150001398733aqst:TwelvePointFiveSeniorSecuredNotesDueJune302025Member2019-07-152019-07-150001398733aqst:A2020AdditionalNotesMember2019-07-152019-07-150001398733aqst:PreFundedWarrantsMember2022-06-300001398733aqst:CommonStockWarrantsMember2022-06-300001398733aqst:CommonStockWarrantsMembersrt:MinimumMember2022-06-3000013987332022-06-300001398733aqst:CommonStockWarrantsMember2023-06-142023-06-140001398733aqst:NewWarrantsMember2025-01-012025-03-310001398733aqst:NewWarrantsMember2026-01-012026-03-310001398733aqst:NewWarrantsMember2026-03-310001398733aqst:MonetizationAgreementMemberaqst:MarathonPangolinRoyaltyLLCMember2020-11-032020-12-310001398733aqst:MonetizationAgreementMember2026-01-012026-03-310001398733aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember2020-06-300001398733aqst:MonetizationAgreementMember2020-11-030001398733us-gaap:RoyaltyMember2026-01-012026-03-310001398733us-gaap:RoyaltyMember2025-01-012025-12-3100013987332025-01-012025-12-310001398733us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001398733us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001398733us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001398733us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001398733us-gaap:WarrantMember2026-01-012026-03-310001398733us-gaap:WarrantMember2025-01-012025-03-310001398733aqst:ManufacturingAndSupplyMember2026-01-012026-03-310001398733aqst:ManufacturingAndSupplyMember2025-01-012025-03-310001398733us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001398733us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001398733us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001398733us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001398733us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001398733us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001398733us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001398733us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001398733aqst:ServiceBasedMemberus-gaap:RestrictedStockUnitsRSUMember2025-12-310001398733aqst:ServiceBasedMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001398733aqst:ServiceBasedMemberus-gaap:RestrictedStockUnitsRSUMember2026-03-310001398733aqst:MarketBasedMemberus-gaap:RestrictedStockUnitsRSUMember2025-12-310001398733aqst:MarketBasedMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001398733aqst:MarketBasedMemberus-gaap:RestrictedStockUnitsRSUMember2026-03-310001398733aqst:MarketConditionRangeOneMemberus-gaap:RestrictedStockUnitsRSUMember2026-03-310001398733aqst:MarketConditionRangeOneMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001398733aqst:MarketConditionRangeTwoMemberus-gaap:RestrictedStockUnitsRSUMember2026-03-310001398733aqst:MarketConditionRangeTwoMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001398733us-gaap:RestrictedStockUnitsRSUMemberaqst:MarketConditionRangeThreeMembersrt:MinimumMember2026-03-310001398733us-gaap:RestrictedStockUnitsRSUMemberaqst:MarketConditionRangeThreeMembersrt:MaximumMember2026-03-310001398733us-gaap:RestrictedStockUnitsRSUMemberaqst:MarketConditionRangeThreeMembersrt:MinimumMember2026-01-012026-03-310001398733us-gaap:RestrictedStockUnitsRSUMemberaqst:MarketConditionRangeThreeMembersrt:MaximumMember2026-01-012026-03-310001398733aqst:MarketConditionRangeFourMemberus-gaap:RestrictedStockUnitsRSUMember2026-03-310001398733aqst:MarketConditionRangeFourMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001398733us-gaap:RestrictedStockUnitsRSUMemberaqst:MarketConditionRangeFiveMembersrt:MinimumMember2026-03-310001398733us-gaap:RestrictedStockUnitsRSUMemberaqst:MarketConditionRangeFiveMembersrt:MaximumMember2026-03-310001398733us-gaap:RestrictedStockUnitsRSUMemberaqst:MarketConditionRangeFiveMembersrt:MinimumMember2026-01-012026-03-310001398733us-gaap:RestrictedStockUnitsRSUMemberaqst:MarketConditionRangeFiveMembersrt:MaximumMember2026-01-012026-03-310001398733aqst:MarketConditionRangeSixMemberus-gaap:RestrictedStockUnitsRSUMember2026-03-310001398733aqst:MarketConditionRangeSixMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001398733aqst:A2025MarketBasedMemberus-gaap:PerformanceSharesMember2026-01-012026-03-310001398733aqst:A2025MarketBasedMemberus-gaap:PerformanceSharesMember2026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeSevenMemberaqst:A2025MarketBasedMember2026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeSevenMemberaqst:A2025MarketBasedMember2026-01-012026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeEightMemberaqst:A2025MarketBasedMember2026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeEightMemberaqst:A2025MarketBasedMember2026-01-012026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeNineMembersrt:MinimumMemberaqst:A2025MarketBasedMember2026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeNineMembersrt:MaximumMemberaqst:A2025MarketBasedMember2026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeNineMembersrt:MinimumMemberaqst:A2025MarketBasedMember2026-01-012026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeNineMembersrt:MaximumMemberaqst:A2025MarketBasedMember2026-01-012026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeTenMemberaqst:A2025MarketBasedMember2026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeTenMemberaqst:A2025MarketBasedMember2026-01-012026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeElevenMembersrt:MinimumMemberaqst:A2025MarketBasedMember2026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeElevenMembersrt:MaximumMemberaqst:A2025MarketBasedMember2026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeElevenMembersrt:MinimumMemberaqst:A2025MarketBasedMember2026-01-012026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeElevenMembersrt:MaximumMemberaqst:A2025MarketBasedMember2026-01-012026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeTwelveMemberaqst:A2025MarketBasedMember2026-03-310001398733us-gaap:PerformanceSharesMemberaqst:VestingConditionRangeTwelveMemberaqst:A2025MarketBasedMember2026-01-012026-03-310001398733us-gaap:PerformanceSharesMembersrt:MaximumMemberaqst:A2025MarketBasedMember2026-01-012026-03-310001398733us-gaap:EmployeeStockOptionMember2025-03-310001398733us-gaap:EmployeeStockOptionMember2025-12-310001398733us-gaap:EmployeeStockOptionMember2026-03-310001398733us-gaap:BlackScholesMertonModelMemberus-gaap:EmployeeStockOptionMember2026-01-012026-03-310001398733aqst:A2022InducementEquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001398733aqst:A2022InducementEquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2026-01-012026-03-310001398733aqst:A2022InducementEquityIncentivePlanMember2026-03-310001398733aqst:SuboxoneProduceLiabilityLitigationMember2024-02-020001398733aqst:SuboxoneProduceLiabilityLitigationMember2024-10-150001398733stpr:CA-BCaqst:SuboxoneProduceLiabilityLitigationMember2024-10-150001398733us-gaap:SubsequentEventMember2026-05-080001398733aqst:TermLoanFacilityMemberaqst:TrancheTwoMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2026-05-120001398733aqst:TermLoanFacilityMemberaqst:TrancheThreeMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2026-05-120001398733aqst:TermLoanFacilityMemberaqst:TrancheFourMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2026-05-120001398733aqst:TermLoanFacilityMemberus-gaap:SubsequentEventMember2026-05-122026-05-12\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 10-Q\n\n☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nOR\n\n☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from _____  to _____\n\nCommission File Number: 001-38599\n\nAquestive Therapeutics, Inc.\n\n(Exact Name of Registrant as Specified in its Charter)\n\nDelaware\n30 Technology Drive, Warren, NJ 07059\n82-3827296\n\n(State or other jurisdiction of Incorporation or organization)\n( 908) 941-1900\n(I.R.S. Employer Identification Number)\n\n(Address, Zip Code and Telephone Number of Registrant’s Principal Executive Offices)\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nCommon Stock, par value $0.001 per shareAQST\nNasdaq Global Market\n\nSecurities registered pursuant to Section 12(g) of the Act:  None\n\nIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes  ☐ No\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes  ☐ No\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934.\n\nLarge accelerated filer☐Accelerated filer☐\n\nNon-accelerated filer☒Smaller reporting company☒\n\n Emerging growth company☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐ Yes  ☒ No\n\nThe number of outstanding shares of the registrant’s common stock, par value of $0.001 per share (the \"Common Stock\"), as of the close of business on May 11, 2026 was 125,450,119.\n\n[Table of](#i65b3f6374bb0418bacd030f2ff357555_7)[Contents](#i65b3f6374bb0418bacd030f2ff357555_7)\n\nAQUESTIVE THERAPEUTICS, INC.\n\nFORM 10-Q\n\nTABLE OF CONTENTS\n\n \n\n  Page No.\n\nPART I – FINANCIAL INFORMATION"}